Grifols, S.A. $GRFS Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 42.0% during the first quarter, Holdings Channel.com reports. The fund owned 352,798 shares of the biotechnology company’s stock after acquiring an additional 104,418 shares during the period. Quantinno Capital Management LP’s holdings in Grifols were worth $2,829,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of GRFS. Bank of Montreal Can boosted its stake in Grifols by 3,205.1% in the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Grifols by 383.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after purchasing an additional 2,221,633 shares in the last quarter. Norges Bank acquired a new position in Grifols during the 4th quarter valued at approximately $18,139,000. Brandes Investment Partners LP raised its holdings in shares of Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after buying an additional 1,838,727 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Grifols by 132.6% in the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after buying an additional 1,387,783 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GRFS shares. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings cut shares of Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Grifols presently has a consensus rating of “Reduce” and an average target price of $10.00.

Grifols Stock Performance

Shares of GRFS stock opened at $7.94 on Monday. Grifols, S.A. has a 52-week low of $6.96 and a 52-week high of $10.84. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The stock has a market cap of $5.40 billion, a PE ratio of 41.79, a price-to-earnings-growth ratio of 0.29 and a beta of 0.66. The business has a 50-day simple moving average of $7.50 and a 200-day simple moving average of $8.13.

Grifols Dividend Announcement

The business also recently declared a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were issued a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is presently 121.05%.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.